PharmSci Today

Gino is joined by James Rickard, Chief Scientific Officer of Biotherapy Services. James, a former Deputy Chief Pharmacist at The Royal London Hospital, has been developing new therapies that will allow pharmacists to successfully treat difficult wounds, such as diabetic leg ulcers. They discuss these new treatments, their remarkable results, and how pharmacists will be central to administering them.

Gino is joined by RPS CEO Paul Bennett, and the two of them talk to Ian McCubbin OBE, Manufacturing Advisor for the UK Vaccine Taskforce, and former Senior Vice President for Global Manufacturing and Supply at GlaxoSmithKline. Ian shares his observations on a long and distinguished career in pharmacy, and more recently on being at the heart of the pandemic response.

In this episode, Gino talks to David Hipkiss, CEO of Enesi Pharma, about developments in solid dose formulation and needle-free delivery for vaccines. Vaccines have come under unprecedented scrutiny during the pandemic, and the two look at ways in which these new technologies could dramatically change the way we store vaccines and deliver them in future.

This episode, Gino talks to Dr Derek O'Hagan, Senior Advisor Vaccines R&D at GlaxoSmithKline. A pharmacist and an expert on the formulation and delivery of vaccines, Derek, has been involved in the creation of vaccines all the way - from basic research to licensing on the market. Derek and Gino look at the latest developments in vaccines for COVID-19 and the many ways a background as a pharmacist has been useful in industry.

It's a busy episode #26 of PharmSci Today, as Gino is joined by the NHS Lothian pharmacy team: Melinda Cuthbert, Claire Hannah, Jenny Scott, Julie Harrold, Fiona Clarke and Anne Neally. The team discuss their experiences of working through the COVID-19 pandemic: both individual and group stories of troubles, triumphs and dedication.

Gino is joined by Professor Chris Molloy, CEO of the Medicines Discovery Catapult, who gives his insider view of innovations in pharmacy and healthcare. The two discuss new ways to drive and support new developments in pharmacy, and examine how COVID-19 has affected the sector and how it develops new treatments and medicines.

This week's guest is Professor Jason Leitch, National Clinical Director of the Scottish Government and a Senior Clinical Advisor to the Scottish Government. Gino and Jason, along with RPS CEO Paul Bennett and RPS Director for Scotland Clare Morrison,  discuss Scottish and English government responses to the pandemic, look at the role of pharmacy during the pandemic, and even find time to look at some recent successes in the fight against COVID-19.

RPS Chief Scientist Gino Martini talks to Ravi Limaye, the Managing Director of medicine and vaccine specialists Wockhardt UK. They look at the science behind different vaccines and the challenges of manufacturing them in bulk, as well as the effect COVID has had upon the UK.

Dr Clive Dix, Head of Vaccine TaskForce, returns to answer questions on new variants, how the UK will have to use COVID-19 vaccines in the future – and the role of pharmacists' in tackling the pandemic.

With the development of vaccines for COVID-19 that require very low storage temperatures, cold chain management will be a vital part of any vaccine delivery system.  RPS Chief Scientist Professor Gino Martini speaks to cold chain experts Michael Hobby and David Davies, both from Checkit, to discover what cold chain management is, how it works and how it can help maximise vaccine stocks.

RPS Chief Scientist Professor Gino Martini speaks to Dr Clive Dix, Deputy Chair of the UK's Vaccine Taskforce. They look at the UK's plans for developing a COVID-19 vaccine: the different options and likelihood of success, as well as the difficulties in storing and distributing the vaccines.

Gino and Sarah continue their chat with Oksana Pyzik, UCL Lead of Global Citizenship Programme on Outbreaks of Infectious Diseases. Oksana is one of the creators of Fight the Fakes, a campaign to raise awareness about the dangers of fake medicines, which is more important than ever while the COVID-19 pandemic continues.

Join Gino and Sarah for the first part of their chat with Oksana Pyzik, UCL Lead of Global Citizenship Programme on Outbreaks of Infectious Diseases. Oksana is one of the creators of Fight the Fakes, a campaign to raise awareness about the dangers of fake medicines, which is more important than ever while the COVID-19 pandemic continues.

Gino and Sarah talk to Dave Tudor, Managing Director of the Medicines Manufacturing Innovation Centre at CPI (Centre for Process Innovation). As the COVID-19 pandemic continues they look at how the pharmaceutical industry has accelerated and innovated its processes, responding like never before to this global crisis.

Gino and Sarah talk to Dr Daria Donati, Head of Business Development & Strategic Technology Partnerships at Cytiva. They discuss the prospects for a COVID-19 vaccine in the UK supported by VMIC, the Vaccines Manufacturing and Innovation Centre, which is supporting the development and manufacture of UK vaccines.

Gino and Sarah talk to Chas Bountra, Professor of Translational Medicine in the Nuffield Department of Clinical Medicine and Associate Member of the Department of Pharmacology at the University of Oxford. The first working COVID vaccine could come from Oxford, and Professor Bountra discusses the secret of the city's success in the fight against the pandemic.

Gino and Sarah talk to Warwick Smith, Director General of the British Generic Manufacturers Association, about the effects COVID-19 has had on the pharmaceutical industry, as well as when and how a vaccine or treatment is likely to become available.

RPS Chief Scientist, Professor Gino Martini, talks to Professor Trevor Jones CBE, visiting professor at King's College London, and a former Head of R&D, at Wellcome. How is a vaccine for COVID-19 being developed? And will it be ready sooner...or later?

Gino and Sarah talk to Dr Brian Henry, Vice President, Drug Product Design at Pfizer. Join them and discover how research into COVID-19 vaccines and treatments is progressing, as well as how pharmacy in general R&D has changed post-COVID.

Professor Martini and Sarah Cahill talk to Dr Sheuli Porkess, Executive Director for Research at the Association of the British Pharmaceutical Industry. They discuss some of the remarkable research efforts currently underway to find treatments and a vaccine for COVID-19.

Gino and Sarah Cahill chat with Rosalind Gittins of Humankind and Dr Amira Guirguis of Swansea University Medical School, about substance misuse issues during the COVID-19 pandemic.

Haseeb Ahmad, Managing Director, UK, Ireland & Nordics Novartis Pharmaceuticals and Country President Novartis UK and President of the ABPI is interviewed by Paul Bennett (CEO, RPS), Prof Gino Martini (Chief Scientist, RPS) and Sarah Cahill (Chief Pharmaceutical Officer's Clinical Fellow) about the Novartis response to COVID-19. Today we cover experimental vaccines and a few existing medicines that are approved for other indications. The RPS, Novartis and the ABPI want to be very clear that they are not endorsing use of these medicines and no treatments have been approved for COVID-19. Their intent is to explain to the society’s listeners the current status of the various clinical studies which are ongoing.

In episode 09 of the PharmSci Today podcast, Paul Bennett (CEO, RPS), Prof Gino Martini (RPS Chief Scientist) and Sarah Cahill (Clinical Fellow, RPS) talk to Richard Saynor (CEO, Sandoz). Richard discusses Sandoz’s response to COVID-19 and how they are maintaining supply chains and supporting clinical trials to combat the coronavirus. Sandoz is one of the largest suppliers of generic medicines in the world and is separate division of Novartis.

New developments in pharmaceutical science, with Professor Gino Martini, Chief Scientist at the Royal Pharmaceutical Society. Gino talks to Dr Hubert Bland from pharmaceutical company Sanofi, discussing the prospects for coronavirus treatments and vaccines. In this podcast, Sanofi will talk about experimental vaccines and a few existing medicines that are approved for other indications. Sanofi wants to be very clear that use of any of its medicines in covid-19 is off-label, entirely experimental at this stage – therefore unproven. Sanofi wants to caution they are not endorsing use of these medicines. Their intent is to explain to the society’s listeners the current status of these studies.

This month, Gino talks to RPS Director of Pharmacy and Member Experience, Robbie Turner, about the threat of coronavirus and looks at the prospects for treatments and a vaccine.

New developments in pharmaceutical science, with Professor Gino Martini, Chief Scientist at the Royal Pharmaceutical Society. This month, Gino talks to Professor David Taylor, Professor Emeritus of Pharmaceutical and Public Health Policy at UCL, about the role of pharmacists in the NHS, the effects of Brexit and investing in the future of healthcare.

New developments in pharmaceutical science, with Professor Gino Martini, Chief Scientist at the Royal Pharmaceutical Society. This month, Helena Rosado of the RPS sits in for Gino and speaks to Dr Janet Halliday about industrial pharmacy, women's health and new drug delivery systems.

Gino introduces Dr Amira Guirguis talking about Novel Psychoactive Substances. This interview was recorded at Swansea as part of the Exploring Global Problems podcast series from Swansea University, where Dr Guirguis is based.

Professor Martini talks with Christine Bond, Professor of Primary Care at the University of Aberdeen and also Editor in Chief of the International Journal of Pharmacy Practice. - How science underpins everything pharmacists do - The role of the Science Research Board (SRB) in the RPS

New developments in pharmaceutical science, with Professor Gino Martini, Chief Scientist at the Royal Pharmaceutical Society.

New developments in pharmaceutical science, with Professor Gino Martini, Chief Scientist at the Royal Pharmaceutical Society. - Personalised medicine: the future of pharmacy? - CAR-T therapies: how are pharmacists involved? - The NHS Long-Term Plan for pharmacy.